
Clinical research
Research on people that tests an advanced regenerative therapy under a reviewed plan, separate from routine treatment.
Under the Advanced Regenerative Bio Act, clinical research is research on people that aims to improve quality of life and widen treatment options. It is grouped into three risk levels. A designated institution needs its research plan reviewed by the review committee, and the highest-risk research also needs approval from the Ministry of Food and Drug Safety.
Before taking part, you must sign a consent form covering the purpose, expected results, adverse reactions, compensation and how to withdraw. The institution may not charge participants for costs related to the research. Clinical trials of medicines are a separate track under the Pharmaceutical Affairs Act.
Practical check: if a clinic calls your treatment part of a study, ask for written proof that the research plan was reviewed, and whether you will be asked to pay anything.
Related terms
- Treatment plan review committee
- The Korean government committee that reviews each advanced regenerative medicine research plan and treatment plan before a designated institution may use it.
- Informed consent
- Your agreement to a treatment after the doctor has explained what it involves, its risks, other options and how likely it is to work.
- Randomized controlled trial
- A study in which people are assigned by chance to receive either the treatment being tested or a comparison, so the groups can be compared fairly.
- Ministry of Food and Drug Safety (MFDS)
- Korea’s regulator for food and medicines, including advanced biopharmaceuticals such as cell therapy products.
Source: Advanced Regenerative Bio Act (Korean, Korea Law Information Center)
Read next
Not sure where to start?
Send your question and any X-ray or MRI report you have. COMEDI, the registered coordinator that runs this guide, replies in writing and can ask a clinic for its written answer and an itemised quote.